drugset / Trial / NCT00155558

A Phase I Trial of HDFL48 in Recurrent or Metastatic Colorectal Cancers

NCT00155558

Phase 1 Completed 16 enrolled National Taiwan University Hospital
Non-randomizedParallel-groupOpen-labelDiagnostic

Summary

To determine the maximum tolerated dose and dose limiting toxicity of 5-FU and leucovorin with novel 48-hour infusion schedule, and to collect toxicity profile at different dose level of 5-FU/LV 48-hour infusion.

Timeline

Start
2001-03
Primary completion
Completion
2005-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Leucovorin Small molecule
Subject fluorouracil Small molecule

Indications